Cardiogenic shock resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Cardiogenic shock is characterized by end organ failure due to systemic hypoperfusion resulting from cardiac failure. Cardiogenic shock is defined by the following hemodymanic parameters:
1- Persistent hypotension:
- Systolic blood pressure <80 to 90 mm Hg, or
- Mean arterial pressure 30 mm Hg lower than baseline
AND
2- Severe decrease in the cardiac index (CI):
- CI <1.8 L/min/ m2 without support, or
- CI <2.0 to 2.2 L/ min/ m2 with support
AND
3- Adequate or elevated filling pressure:
- Left ventricular end-diastolic pressure >18 mm Hg, or
- Right ventricular end-diastolic pressure >10 to 15 mm Hg
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Cardiogenic shock is a life-threatening condition and must be treated as such irrespective of the causes.
Common Causes
- Pump failure secondary to MI
- Mechanical complications of MI
- Ventricular septal rupture
- Free wall rupture
- Papillary muscle rupture
- Arrythmia
- Acute heart failure
- Acute valve regurgitation
- Aortic dissection[1]
Management
Shock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABCD Airway / O2 / 2 wide bore IV access / 12-lead ECG / focused H&P / CXR PA / Arterial line monitoring | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hemodynamic optimization
❑ Fluid therapy(guided by PCWP,SaO2,CO) ❑ Contributing factors(-ve inotropes,diuretics) ❑ Vasopressors (Norepinephrine,Dopamine) ❑ Correct Acidosis (affect vasopressors) ❑ Correct Hypoxemia (affect vasopressors) ❑ Medications (Aspirin,Heparin,GP IIb/IIIa) | Do Not give β Blockers Ca Channel antagonist | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ECG evidence of STEMI † | ECG inconclusive No ST/Limited ST/delayed CS | ECG: - ve Clinical history of HF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STEMI | Echocardiography rule out Acute valvular lesions | Heart failure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Echocardiography to associated valvular causes †† | *Pump failure RV/LV *High risk NSTEMI‡ | Acute severe MR VSR Critical AS,MS | Aortic dissection Tamponade | Treatment of heart failure ❑ oxygen ❑ Diuretics ❑ Morphine ❑ Vasodilators | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PCI capable center | IABP | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PCI Non-capable center | Urgent PCI | Surgical correction Valve surgery ± CABG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
If 1-2 vessels do PTCA | If severe lesion & 3 vessels do CABG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transfer to PCI center¶ < 90 min | Transfer to PCI center > 90 min | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Urgent Transfer to PCI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thrombolytics | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Get stable | Still Non stable * Hypotension * ECG evidence | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transfer to PCI center within 3-24 hrs after Thrombolytics | IABP+ Urgent Transfer to PCI center | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
† New ST elevation at the J point in at least 2 contiguous leads of 2 mm in men or 1.5 mm in women in leads V2-V3 and/or of 1 mm in other contiguous chest leads or the limb leads.
†† Early echocardiography should be done before PCI as long as the patient is not crashing, as it may change the treatment course.
‡ High risk NSTEMI is when Non ST-elevation MI is associated with
- Hemodynamic instability or cardiogenic shock
- Severe left ventricular dysfunction or heart failure
- Sustained ventricular arrhythmias
- Recurrent or persistent rest angina despite intensive medical therapy
- New or deteriorating mitral regurgitation
- New ventricular septal defect
¶ Door To Baloon, D2B
Special Consideration in CS with STEMI
- Donot give negative inotropic medications (Ca channel blocker-β Blockers)
- Clopidogrel should be stopped till after angiography.
- Lidocaine shouldnot be used in ventricular arrythmia, and if used must be with the lowest dose.
Do's
- 250 mL of isotonic saline should be given empirically as an intravenous volume challenge before the right heart catheterization in patients with suspected CS as long as no clinical evidence of respiratory distress or radiological evidence of pulmonary congestion.
- Correct metabolic acidosis caused by global tissue hypoperfusion, as acidosis can significantly reduce the responsiveness of the vasopressors.[2]
- Monitor the hypovolemic state and hemodynamic status as cardiogenic shock occurs in 5-8% of hospitalized STEMI patient.[3]
- Using smaller combined doses of vasopressors and inotropes is preferable over a single agent used at higher doses to avoid dose-related adverse effects.[2]
- Perform PCI within 90 minutes of initial hospital presentation.
- Cardiac Echocardiography (Transthoracic) is helpful to rule out mechanical problems when the initial ECG findings are not conclusive or when the cardiogenic shock occurs with the first non anterior MI.[4]
- Echocardiography should be performed early before PCI unless the diagnosis is extensive anterior MI and the patient is undergoing prompt percutaneous coronary intervention (PCI).[4]
- Transfer the STEMI patients with cardiogenic shock to PCI irrespective to time delay from time of presentation.
- Use IABP when there is rapid deterioration of hemodynamic paramaters, while the on vasopressors and inotropic support.
- Use IABP with rapid initiation of Thrombolytics < 30 min prior transfer, when there is anticipated very long delay in transfer, low risk of fibrinolysis and MI symptoms > 3 hours.
- Use the fibrinolytic agents combined with vigorous vasopressor and IABP
Don'ts
- Do not routinely use an intraaortic balloon pump (IABP)in all MI patients complicated with cardiogenic shock (CS), especially when there is no mechanical complications (VSD,MVR) and when the patient is scheduled for revascularization intervention.
References
- ↑ Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter
|month=
ignored (help) - ↑ 2.0 2.1 Overgaard, CB.; Dzavík, V. (2008). "Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease". Circulation. 118 (10): 1047–56. doi:10.1161/CIRCULATIONAHA.107.728840. PMID 18765387. Unknown parameter
|month=
ignored (help) - ↑ Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter
|month=
ignored (help) - ↑ 4.0 4.1 Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter
|month=
ignored (help)